Mantle Cell Lymphoma clinical trials in North Carolina
21 active Mantle Cell Lymphoma trials with a site in North Carolina. Describe your situation to see which ones look like a fit.
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- DALY II USA/ MB-CART2019.1 for DLBCL
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
- Study of SGR-1505 in Mature B-Cell Neoplasms
- A Long-term Extension Study of PCI-32765 (Ibrutinib)
- A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- A Study of ARC-02 in B-cell NHL
- Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
- A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.